行情

PRTA

PRTA

Prothena Corp
NASDAQ

实时行情|Nasdaq Last Sale

10.80
+0.56
+5.47%
已收盘, 16:00 11/19 EST
开盘
11.92
昨收
10.24
最高
11.96
最低
10.76
成交量
29.78万
成交额
--
52周最高
14.77
52周最低
6.71
市值
4.31亿
市盈率(TTM)
-5.4895
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

PRTA 新闻

  • Prothena up 8% on Evercore upgrade
  • Seeking Alpha - Article.18小时前
  • Prothena (NASDAQ:PRTA) Is In A Good Position To Deliver On Growth Plans
  • Simply Wall St..18小时前
  • Benzinga's Top Upgrades, Downgrades For November 19, 2019
  • Benzinga.19小时前
  • Evercore downgrades bluebird bio and Clovis in premarket analyst action
  • Seeking Alpha - Article.21小时前

更多

所属板块

生物技术和医学研究
+2.16%
制药与医学研究
+0.78%

热门股票

名称
价格
涨跌幅

PRTA 简况

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). The Company has generated monoclonal antibodies that selectively bind to amyloidogenic (diseased) forms of the Transthyretin (TTR)-mediated amyloidosis (ATTR) protein. The Company's pipeline also includes late discovery-stage programs for which the Company is testing the efficacy of antibodies in preclinical models of diseases related to amyloid or cell adhesion.
展开

Webull提供Prothena Corporation PLC的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。